In this review:
This review is a concise summary of the important pharmacological and clinical characteristics of pembrolizumab (Keytruda®), which is available in New Zealand for the treatment of unresectable or metastatic melanoma. Expert commentary on the use of pembrolizumab from a clinical practice perspective is provided by Dr Rosalie Fisher, medical oncologist at Auckland Hospital.
Download PDF